The effects of near-complete estrogen deprivation on heart health in women with breast cancer
Cardiovascular Impact of Near-complete Estrogen Deprivation for Breast Cancer
This study is looking at how a treatment that lowers estrogen levels in premenopausal women with hormone receptor-positive breast cancer might affect heart health, helping to find out if there are any risks for heart problems during this therapy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-11082978 on NIH RePORTER |
What this research studies
This research investigates how near-complete estrogen deprivation therapy, which is used to improve survival rates in premenopausal women with hormone receptor-positive breast cancer, affects cardiovascular health. The study aims to understand the risks of cardiovascular issues, such as atherosclerosis and coronary artery disease, that may arise due to early hypoestrogenemia caused by this therapy. By using advanced imaging techniques like cardiac magnetic resonance imaging, researchers will assess the heart health of women undergoing this treatment to identify early signs of cardiovascular compromise.
Who could benefit from this research
Good fit: Ideal candidates for this research are premenopausal women diagnosed with hormone receptor-positive breast cancer who are starting near-complete estrogen deprivation therapy.
Not a fit: Patients who are not premenopausal or those with non-hormone receptor-positive breast cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better monitoring and management of cardiovascular health in women undergoing breast cancer treatment, potentially improving their overall quality of life.
How similar studies have performed: Previous research has indicated cardiovascular risks associated with estrogen deprivation in women, suggesting that this approach could yield important insights into managing these risks.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Thomas, Alexandra — Duke University
- Study coordinator: Thomas, Alexandra
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.